Association of Circulating Tumor DNA (ctDNA) to Monitoring Treatment Response in Urothelial Carcinoma: A Comprehensive Systematic Review
DOI:
https://doi.org/10.57214/jusika.v10i1.1141Keywords:
Bladder Cancer, Liquid Biopsy, Minimal Residual Disease, Treatment Monitoring, Urothelial CarcinomaAbstract
Circulating tumor DNA (ctDNA) has emerged as a promising liquid biopsy biomarker for real-time monitoring of tumor dynamics. In urothelial carcinoma (UC), effective monitoring of treatment response remains a clinical challenge due to the limitations of conventional imaging and invasive procedures. This systematic review aims to synthesize the existing evidence on the association between ctDNA dynamics and treatment response monitoring across various stages and therapeutic settings. A comprehensive systematic review was conducted. We included cohort studies, randomized controlled trials, and meta-analyses that evaluated ctDNA in UC patients undergoing treatment. Data were extracted on patient population, methodology, treatment, sampling strategy, clinical outcomes, and statistical associations. The review encompassed 80 studies. Baseline ctDNA positivity was strongly prognostic, associated with a 4- to 6-fold increased risk of recurrence or death (HR 4.23-6.56). Dynamic ctDNA clearances or significants reduction during treatment, were strongly associated with improved outcomes. Showing hazard ratios for adverse events as low as 0.10-0.31. ctDNA demonstrated time advantages of 53-90 days over radiographic detection. ctDNA is a potent tool for monitoring treatment response in urothelial carcinoma. It provides superior prognostic and offers a significant lead time for detecting treatment failure. Future research must focus on standardizing methodologies and validating ctDNA-guided therapeutic.
References
Al-Showbaki, L., Wilson, B., Tamimi, F., Moltó, C., Mittal, A., Cescon, D., & Amir, E. (2023). Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: A systematic review. Journal for ImmunoTherapy of Cancer.
Azevedo, R., Soares, J., Peixoto, A., Cotton, S., Lima, L., Santos, L., & Ferreira, J. (2018). Circulating tumor cells in bladder cancer: Emerging technologies and clinical implications foreseeing precision oncology. Urologic Oncology.
Crupi, E., Costa de Padua, T., Marandino, L., Raggi, D., Dyrskjøt, L., Spiess, P. E., Sonpavde, G., Kamat, A., & Necchi, A. (2023). Circulating tumor DNA as a predictive and prognostic biomarker in the perioperative treatment of muscle-invasive bladder cancer: A systematic review. European Urology Oncology.
Das, D. K. (2021). Insights on ctDNA-guided adjuvant immunotherapy in urothelial carcinoma. Oncology Times.
de Kruijff, I. D., Beije, N., Martens, J., de Wit, R., Boormans, J., & Sleijfer, S. (2020). Liquid biopsies to select patients for perioperative chemotherapy in muscle-invasive bladder cancer: A systematic review. European Urology Oncology.
Dyrskjøt, L., Birkenkamp-Demtröder, K., Nordentoft, I., Lindskrog, S., Strandgaard, T., Milling, R. V., Körner, S., et al. (2025). Abstract CT101: ctDNA-guided immunotherapy following cystectomy in patients with urothelial carcinoma: Preliminary results from the TOMBOLA trial. Cancer Research.
Galsky, M. D., Gschwend, J. E., Milowsky, M. I., Schenker, M., Valderrama, B. P., Tomita, Y., Bamias, A., et al. (2025). Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274. Annals of Oncology.
Gao, X., Qi, W., Li, J., Xia, Y., Ding, P., Guo, D., Shi, B., & Jiang, X. (2025). Prognostic and predictive role of circulating tumor DNA detection in patients with muscle invasive bladder cancer: A systematic review and meta-analysis. Cancer Cell International.
Grosso, A., Cadenar, A., Pillozzi, S., Carli, G., Lipparini, F., Di Maida, F., Pichler, R., et al. (2025). Circulating tumor DNA in muscle-invasive bladder cancer: A systematic review. Actas Urológicas Españolas.
Haoyang, L., Chen, J., Huang, Y., & Zeng, H. (2023). 2405P prognostic significance of circulating tumor DNA in patients with urothelial carcinoma: A systematic review and meta-analysis. Annals of Oncology.
Herranz, R., Oto, J., Plana, E., Fernández-Pardo, Á., Cana, F., Martínez-Sarmiento, M., Vera-Donoso, C., España, F., & Medina, P. (2021). Circulating cell-free DNA in liquid biopsies as potential biomarker for bladder cancer: A systematic review. Cancers.
Jackson-Spence, F., Toms, C., O’Mahony, L. F., Choy, J., Flanders, L., Szabados, B., & Powles, T. (2023). IMvigor011: A study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. Future Oncology.
Katims, A. B., Lenis, A., Shah, R. H., Chu, C. E., Ratna, N., Regazzi, A., Pietzak, E., et al. (2023). Assessing the utility of a cell-free tumor (ct)DNA assay (MSK-ACCESS) in patients (pts) with node-positive (N+) muscle-invasive bladder cancer (MIBC) undergoing neoadjuvant chemotherapy (NAC). Journal of Clinical Oncology.
Khetrapal, P., Lee, M., Tan, W., Dong, L., de Winter, P., Feber, A., & Kelly, J. (2018). The role of circulating tumour cells and nucleic acids in blood for the detection of bladder cancer: A systematic review. Cancer Treatment Reviews.
Laukhtina, E., Pradère, B., Mori, K., Schuettfort, V., Quhal, F., Mostafaei, H., Motlagh, R. S., et al. (2021). Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review. Urologic Oncology.
Li, A., Lou, E., Leder, K., & Foo, J. (2025). Early circulating tumor DNA kinetics as a dynamic biomarker of cancer treatment response. JCO Clinical Cancer Informatics.
Lindskrog, S., & Dyrskjøt, L. (2023). Towards circulating tumor DNA-guided treatment of muscle-invasive bladder cancer. Translational Andrology and Urology.
Liu, H., Chen, J., Huang, Y., Zhang, Y., Ni, Y., Xu, N., Zhao, F., et al. (2024). Prognostic significance of circulating tumor DNA in urothelial carcinoma: A systematic review and meta-analysis. International Journal of Surgery.
Ma, Q., Hou, S., Ma, H., Gao, J., & Song, D. (2025). Prognostic significance of circulating tumor DNA in urothelial carcinoma patients undergoing immune checkpoint inhibitor therapy: A systematic review and meta-analysis. Frontiers in Immunology.
Maas, M., Bedke, J., Stenzl, A., & Todenhöfer, T. (2018). Can urinary biomarkers replace cystoscopy? World Journal of Urology.
Mehrotra, S., Redla, A. C., Tan, J. K., Ghose, A., Maniam, A., Boussios, S., Banna, G., Das, P., Adeleke, S., & Sharma, A. (2025). IUC24417-83 correlation of circulating tumor DNA with oncological endpoints in metastatic urothelial cancer: A systematic review and meta-analysis of phase II/III clinical trials. The Oncologist.
Mittal, A., Valiente, C. M., Tamimi, F., Di Iorio, M., Al-Showbaki, L., Cescon, D., & Amir, E. (2023). Utility of ctDNA in predicting relapse in solid tumors after curative therapy: A meta-analysis. JNCI Cancer Spectrum.
Powles, T., Chang, W., Yamamoto, Y., Muñoz-Langa, J., Reyes, F., Peer, A., Yu, E. Y., et al. (2024). Quantitative circulating tumor DNA (ctDNA) assessment in patients (pts) with advanced urothelial carcinoma (UC) treated with pembrolizumab (pembro) or platinum-based chemotherapy (chemo) from the phase 3 KEYNOTE-361 trial. Journal of Clinical Oncology.
Powles, T., Kann, A. G., Castellano, D., Gross-Goupil, M., Nishiyama, H., Bracarda, S., Jensen, J. B., et al. (2025). ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. New England Journal of Medicine.
Redla, C., Mehrotra, S., Tan, J. K., Ghose, A., Shah, A., Kotecha, P., Sharma, A., Das, P., Teoh, J., & Vasdev, N. (2025). IUC24418-84 biomarkers detecting minimal residual disease for predicting risk of relapse in operable urothelial cancer: A systematic review and meta-analysis of phase II/III clinical trials. The Oncologist.
Shohdy, K., Franco, A. O., Saud, A., Abdeltawab, R., Howell, M., Cook, N., Thistlethwaite, F., et al. (2024). 86O serial monitoring of circulating tumor DNA (ctDNA) as a tumor-agnostic biomarker to inform clinical outcomes of patients receiving experimental cancer medicine. ESMO Open.
St-Laurent, M. P., Eigl, B., Yuan, R., Chang, S., & Black, P. C. (2025). NEO-BLAST: Neoadjuvant therapy for bladder cancer followed by active surveillance vs treatment. Journal of Clinical Oncology.
Suartz, C., Martinez, L. M., Cordeiro, M., Botelho, L. A. A., Gallutti, F. P., Mota, J. M., Leite, K. R. M., Toren, P., Nahas, W. C., & Ribeiro-Filho, L. (2024). Honing the hunt: A comprehensive review of cell-free tumor DNA to predict neoadjuvant therapy efficacy in bladder cancer. Clinical Genitourinary Cancer.
van Dorp, J., Pipinikas, C., van Dijk, N., Jones, G., Gil-Jimenez, A., Marsico, G., van Montfoort, M. V., et al. (2022). Abstract 1273: Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid-biopsy assessment of plasma and urine ctDNA using the RaDaR assay. Cancer Research.
Young, M., Szabados, B., Assaf, Z., Jackson-Spence, F., Nally, E., Wells, C., Suárez, C., Castellano, D., Powles, T., & Banchereau, R. (2024). Predictive value of dynamic changes in ctDNA and baseline biomarkers with neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Journal of Clinical Oncology.
Zhan, Y., Ruan, X., Wu, Y., Chun, T., Yao, C., Shi, R., Liu, J., et al. (2025). Surveillance of the genetic signature in circulating tumor DNA for guiding adjuvant chemotherapy in urothelial carcinoma: Protocol for a pilot randomized controlled trial. JMIR Research Protocols.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Jurnal Sains dan Kesehatan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
